Amyotrophic Lateral Sclerosis (ALS) Treatment Market Opportunity Analysis-2026

GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027

© Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Overview North America is expected to hold a dominant position in the market, increasing focus of manufacturers on novel drug development for ALS North America is expected to hold a dominant position in the Amyotrophic Lateral Sclerosis Treatment Market, as major companies present in the region are focusing on collaborations for product development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) for the treatment of ALS. Companies based in emerging economies of Asia Pacific are focusing on developing novel drugs for treatment of ALS. For instant major companies such as Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceutical Company Ltd are developing drugs for treatment of ALS.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time.

According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per 100,000 people in 2012.

Browse Research Reports: https://www.coherentmarketinsights.com/ongoing-insight/cancervaccines-market-1209 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION The increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral sclerosis (ALS) treatment market in the near future.

Approval of novel innovative drugs is expected to boost growth in amyotrophic lateral sclerosis treatment market In May 2017, The U.S. Food and Drug Administration (FDA) approved Radicava (edaravone), an innovative drug used in the treatment of amyotrophic lateral sclerosis (ALS). This was the first drug to be approved after over 20 years since the last FDA-approved drug for ALS. The approval of this drug would provide an additional option for patients suffering from this deadly disease. Increasing incidence of ALS is expected to increase the adoption rate of this drug, in turn, boosting market growth. The drug has already been approved in Japan and South Korea in 2015.

Initiatives taken by some associations to increase awareness about diagnosis and treatment of ALS among population is also expected to drive market growth during forecast period (20172025). For instance in 2014, the ALS Ice Bucket Challenge, a social media–centered campaign, received extensive public visibility and created increased awareness of ALS. In 2015, a group of ALS organizations in the U.S., including the ALS Association, Les Turner ALS Foundation, and ALS Therapy Development Institute, re-introduced the Ice Bucket Challenge to raise further funds and spread awareness about ALS among population.

Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/1206 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Major players are collaborating with various research institutes and companies for the development of drug for amyotrophic lateral sclerosis treatment In December 2017, Mitsubishi Tanabe Pharma Corporation, Order made Medical Research Corporation and Trans Chromosomics Inc. have completed strategic collaboration for the development of antibody drug to treat neurodegenerative diseases such as ALS. Takeda Pharmaceutical Company Ltd. collaborated with Montreal Neurological Institute for the discovery of new drugs for ALS in the same month. In 2016, Evotec and Celgene Corporation have entered into a strategic drug discovery for the development of new drugs for neurodegenerative diseases such as ALS. In 2013 Janssen Research & Development, Division of Janssen Pharmaceutica NV, and Johnson & Johnson collaborated, with three prominent Belgian academic institutions and research centers for the discovery of new treatment drugs for neurodegenerative diseases such as ALS. Major players operating in the global amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1206 © Coherent market Insights. All Rights Reserved

ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.

SERVICES INDUSTRY ANALYSIS

CUSTOMIZED RESEARCH

SYNDICATED RESEARCH

MARKET INTELLIGENCE SERVICES

CONSULT STUDIES

COUNTRY SPECIFIC STUDIES

© Coherent market Insights. All Rights Reserved

ABOUT CMI SECTOR COVERAGE

BIOTECHNOLOGY

CLINICAL DIAGNOSTIC

HEALTHCARE IT

MEDICAL DEVICES

MEDICAL IMAGING

PHARMACEUTICAL

OUR CLIENTS

 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry

 Component Providers and System Integrators

 Private and Government organization

 Distributors, Retailors and Value Added Resellers

 Outsourcing Companies

 Healthcare IT Solutions Developers

 Universities and Business Schools.

© Coherent market Insights. All Rights Reserved

KEY STATS

RESEARCH SOLUTIONS

100+

FEASIBILITY STUDIES

Insights Published Per Year

GLOBAL REPORTS

150+

Consulting Projects Till Date

COUNTRY ANALYSIS CONSULT PROJECTS

125+

Clients Worldwide Per Year

110+

SURVEY RESEARCH

EXCEL FORECAST DATABASE

CUSTOMIZED SOLUTIONS

COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS

Analysts and Contract Consultants

Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702

© Coherent market Insights. All Rights Reserved